News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Puma Biotechnology Gains After Rival Drug Data Show No Threat


5/20/2013 7:57:20 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Puma Biotechnology Inc. (PBYI), the maker of an experimental cancer drug, had its biggest two-day gain in seven months after data on a competitor medicine did nothing to diminish analysts’ expectations. Puma gained 7.4 percent to $37.36 at 4:01 p.m. New York time, and has increased 17 percent in the last two days, the most since October. The shares of the Los Angeles-based biotechnology company have risen 99 percent this year. Puma will start late-stage testing in the second quarter of its experimental breast-cancer drug neratinib and also is studying the therapy in non-small cell lung cancer, the company said in a May 9 statement. Chief Executive Officer Alan H. Auerbach sold his previous company, Cougar Biotechnology Inc., for about $1 billion to Johnson & Johnson before gaining approval of a prostate cancer medicine.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES